Mannkind price to sales ratio MNKD

Market value divided by revenue over the last twelve months, since 2016.

Today, Oct 23, 2026: 2.6×
10-year median: 6.7×
Against its 10-year history: 12th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.4× to 29.0×
Peer median: 1.6×

Mannkind's price to sales ratio is 2.6× as of Oct 23, 2026.

That is below its ten-year median of 6.7×, lower than on 88% of days in the last ten years.

Over that time it ranged from 0.4× in May 2017 to 29.0× in Mar 2018.

The median for 10 large drugmakers of a similar size is 1.6×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.6×	2.0×	5.7×
2025	5.7×	3.6×	6.7×
2024	7.0×	5.0×	7.9×
2023	5.6×	5.2×	19.4×
2022	18.2×	9.1×	18.2×
2021	13.5×	11.6×	22.8×
2020	11.6×	3.2×	14.7×
2019	4.5×	3.8×	15.2×
2018	11.2×	10.6×	29.0×
2017	13.9×	0.4×	19.5×
2016	1.9×	1.6×	2.1×

Against its peers

Companies in Drug Manufacturers - General nearest Mannkind's size, closest first, today.

Company	Price to sales ratio
MNKDMannkind	2.6×
AMPHAmphastar Pharmaceuticals	1.5×
OMEROmeros	n/m
ABUSArbutus Biopharma	4.6×
COLLCollegium Pharmaceutical	0.9×
PCRXPacira BioSciences	1.9×
ANABAnaptysbio	n/m
PAHCPhibro Animal Health	1.0×
ANIPANI Pharmaceuticals	1.7×
CRMDCorMedix	1.3×
ZVRAZevra Therapeutics	4.3×
Peer median	1.6×

Where Mannkind ranks

#52of 157Large drugmakers with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Mannkind

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.